ITC was accepted and improved additional benefit rating
In the recent early benefit assessment of nivolumab, the G-BA not only accepted the submitted ITC, but this also resulted in a
Category: Early benefit assessments
First COVID-19 drug has been assessed by G-BA
The antiviral drug remdesivir (brand name: Veklury) has been the first drug targeting COVID-19, which has undergone an early benefit assessment. It
G-BA assessment of CAR-T therapy Tecartus
The G-BA has now completed its benefit assessment of the CAR-T therapy, Tecartus, which is indicated for the treatment of mantle cell
G-BA assessments of new indications
The AMNOG law dictates that every pharmaceutical product with a new chemical entity which received its marketing authorization on or after 1
Joint HTAs are finally coming to Germany
It’s been a long time in the making, but now the G-BA finally accepted a compromise on joint HTAs conducted at the